Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
Robust top and bottom-line growth during the quarter and YTD
FINANCIAL PROFILE
Continuing operations¹
Change vs. PY
Q3
9M
Change vs. PY
USD million
2023
% USD
% CC²
2023
% USD
% CC²
Net sales
11,782
12
12
34,017
8
10
Core operating income²
4,405
17
21
12,551
13
19
Operating income
1,762
-4
13
7,187
16
31
Net income
1,513
14
37
5,934
25
41
Core EPS (USD)²
1.74
EPS (USD)
0.73
22
24
29
4.95
21
28
20
45
2.84
31
49
Free cash flow²
5,043
24
11,019
27
1. As defined on page 37 of the Condensed Interim Financial Report, Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities
results and constant currencies are non-IFRS measures. Details regarding non-IFRS measures can be found starting on page 48 of the Condensed Interim Financial Report.
2. Core
Unless otherwise noted, all growth rates refer to same period in PY.
24 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation